Evidence-based pharmacological treatment of substance use disorders and pathological gambling

Current Drug Abuse Reviews

Volumn 5, Issue 1, 2012, Pages 3-31

  van den Brink, Wim ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Addiction; Dependence; Pathological gambling; Pharmacogenomics; Pharmacological treatment; Review; Smoking; Substance use disorders

Indexed keywords

4 HYDROXYBUTYRIC ACID; ACAMPROSATE; AMFEBUTAMONE; ANXIOLYTIC AGENT; BACLOFEN; CLONIDINE; CYTISINE; DISULFIRAM; DRUGS USED IN THE TREATMENT OF ADDICTION; FLUOXETINE; GABAPENTIN; MECAMYLAMINE; NALMEFENE; NALOXONE; NALTREXONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; PLANT MEDICINAL PRODUCT; RIMONABANT; SELEGILINE; SERTRALINE; TARANABANT; TOPIRAMATE; UNINDEXED DRUG; VARENICLINE;

ABDOMINAL CRAMP; ALCOHOLISM; CANNABIS ADDICTION; CARDIOTOXICITY; COCAINE DEPENDENCE; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; EPILEPTIC STATE; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HICCUP; HUMAN; HYPERICUM PERFORATUM; HYPOTENSION; IRRITABILITY; JAW PAIN; LIVER TOXICITY; LOW DRUG DOSE; MEMORY DISORDER; MONOTHERAPY; MOUTH DISEASE; NAUSEA; NEUROPATHIC PAIN; NICOTINE REPLACEMENT THERAPY; OPIATE ADDICTION; PARESTHESIA; PATHOLOGICAL GAMBLING; PATHOPHYSIOLOGY; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RESPIRATORY TRACT INFECTION; REVIEW; RHINITIS; SIDE EFFECT; SKIN IRRITATION; SKIN SENSITIVITY; SMOKING CESSATION; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; TOOTH DISEASE; TREATMENT DURATION; URINE RETENTION; WEAKNESS; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

EID: 84860282580     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/1874473711205010003     Document Type: Review

References (298)

1. Rehm J, Taylor B, Room R. Global burden of disease from alcohol, illicit drugs and tobacco. Drug Alcohol Rev 2006; 25(6): 503-13.
2. Andlin-Sobocki P, Rehm J. Cost of addiction in Europe. Eur J Neurol 2005; 12(Suppl) 1: 28-33.
3. UNODC-WHO. UNODC-WHO Joint program on drug dependence treatment and care. UNODC-WHO/Vienna-Geneva, 2009.
4. Fowler T, Lifford K, Shelton K, et al. Exploring the relationship between genetic and environmental influences on initiation and progression of substance use. Addiction 2007; 102(3): 413-22.
5. Agrawal A, Lynskey MT. Are there genetic influences on addiction: evidence from family, adoption and twin studies. Addiction 2008; 103(7): 1069-81.
6. Slutske WS, Eisen S, True WR, et al. Common genetic vulnerability for pathological gambling and alcohol dependence in men. Arch Gen Psychiatry 2000; 57(7): 666-73
7. Slutske WS, Zhu G, Meier MH, et al. Genetic and environmental influences on disordered gambling in men and women. Arch Gen Psychiatry 2010; 67(6): 624-30.
8. Kendler KS, Prescott CA, Myers J, et al. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch Gen Psychiatry 2003; 60(9): 929-37.
9. Kendler KS, Myers J, Prescott CA. Specificity of genetic and environmental risk factors for symptoms of cannabis, cocaine, alcohol, caffeine, and nicotine dependence. Arch Gen Psychiatry 2007; 64(11): 1313-20.
10. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010; 35(1): 217-38.
11. Dawson DA, Grant BF, Stinson FS, et al. Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction 2005; 100(3): 281-92
12. De Bruijn C, van den Brink W, de Graaf R, et al. The three year course of alcohol use disorders in the general population: DSM-IV, ICD-10 and the Craving Withdrawal Model. Addiction 2006; 101(3): 385-92.
13. Hser YI, Hoffman V, Grella CE, et al. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001; 58(5): 503-8.
14. Van den Brink W, van Ree JM. Pharmacological treatments for heroin and cocaine addiction. Eur Neuropsychopharmacol 2003; 13(6): 476-87.
15. Van den Brink W, Haasen C. Evidenced-based treatment of opioiddependent patients. Can J Psychiatry 2006; 51(10): 635-46.
16. Nutt D, King LA, Saulsbury W, et al. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007; 369(9566): 1047-53.
17. Nutt DJ, King LA, Phillips LD; Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010; 376(9752): 1558-65.
18. van Amsterdam J, Opperhuizen A, Koeter M, et al. Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. Eur Addict Res 2010; 16(4): 202-7.
19. Potenza MN. Should addictive disorders include non-substancerelated conditions? Addiction 2006; 101 Suppl 1: 142-51.
20. Petry NM. Should the scope of addictive behaviors be broadened to include pathological gambling? Addiction 2006; 101 (Suppl 1): 152-60.
21. van Holst RJ, van den Brink W, Veltman DJ, et al. Why gamblers fail to win: a review of cognitive and neuroimaging findings in pathological gambling. Neurosci Biobehav Rev 2010; 34(1): 87-107.
22. American Psychiatric Association. The future of psychiatric diagnosis: substance-related disorders. 2010; Avaliable at: www.dsm5.org/ProposedRevisions/Pages/Substance-RelatedDisorders.aspx
23. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340(9): 685-91.
24. Crunelle CL, Miller ML, Booij J, et al. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. Eur Neuropsychopharmacol 2010; 20(2): 69-79.
25. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; 1: CD000146.
26. Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs 2010; 70(18): 2357-72.
27. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008; 63(8): 717-24.
28. Tsukahara H, Noda K, Saku K. A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). Circ J 2010; 74(4): 771-8
29. Ebbert JO, Burke MV, Hays JT, et al. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009; 11(5): 572-6.
30. Shah SD, Wilken LA, Winkler SR, et al. Systematic review and meta-analysis of combination therapy for smoking cessation. J Am Pharm Assoc (2003). 2008; 48(5): 659-65.
31. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2010; 12: CD006103.
32. Gonzales D, Rennard SI, Nides M, et al. Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296(1): 47-55.
33. Jorenby DE, Hays JT, Rigotti NA, et al. Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustainedrelease bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296(1): 56-63.
34. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo-and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166(15): 1561-8
35. Tonstad S, Tønnesen P, Hajek P, et al. Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006; 296(1): 64-71
36. Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805. doi: 10.1136/bmj.b3 805
37. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; 1: CD000031.
38. Scharfenberg G, Benndorf S, Kempe G. Cytisine (Tabex) as a pharmaceutical aid in stopping smoking. Dtsch Gesundheitsw 1971; 26(10): 463-5.
39. Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Cochrane Database Syst Rev 1997; 3: CD000124.
40. Rose JE, Levin ED, Behm FM, et al. Combined administration of agonist-antagonist as a method of regulating receptor activation. Ann N Y Acad Sci 1995; 10; 757: 218-21.
41. Lancaster T, Stead LF. Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev 1998; 2: CD001009.
42. Rose JE, Behm FM, Westman EC, et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 1994; 56(1): 86-99.
43. Rose JE, Behm FM, Westman EC. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol 1998; 6(3): 331-43.
44. Glover ED, Laflin MT, Schuh KJ, et al. A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. Addiction 2007; 102(5): 795-802
45. Johnson TS. A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline. J Am Acad Nurse Pract 2010; 22(10): 557-63.
46. Parsons A, Ingram J, Inglis J, et al. A proof of concept randomised placebo controlled factorial trial to examine the efficacy of St John's wort for smoking cessation and chromium to prevent weight gain on smoking cessation. Drug Alcohol Depend 2009; 102(1-3): 116-22.
47. Sood A, Ebbert JO, Prasad K, et al. A randomized clinical trial of St. John's wort for smoking cessation. J Altern Complement Med 2010; 16(7): 761-7.
48. David SP, Lancaster T, Stead LF, et al. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev 2006; 4: CD003086.
49. O'Malley SS, Cooney JL, Krishnan-Sarin S, et al. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med 2006; 166(6): 667-74.
50. Covey LS, Glassman AH, Stetner F. Naltrexone effects on shortterm and long-term smoking cessation. J Addict Dis 1999; 18(1): 31-40.
51. King A, de Wit H, Riley RC, et al. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res 2006; 8(5): 671-82.
52. Toll BA, White M, Wu R, et al. Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial. Drug Alcohol Depend 2010; 111(3): 200-6
53. Cahill K, Ussher MH. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev 2007; 4: D005353.
54. Rigotti NA, Gonzales D, Dale LC, et al. CIRRUS Study Group. A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction 2009; 104(2): 266-76.
55. Morrison MF, Ceesay P, Gantz I, Kaufman KD, Lines CR. Randomized, controlled, double-blind trial of taranabant for smoking cessation. Psychopharmacology (Berl) 2010; 209(3): 245-53.
56. Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. Cochrane Database Syst Rev 2000; 4: CD002849.
57. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004; (3): CD000058.
58. Cerny EH, Cerny T. Vaccines against nicotine. Hum Vaccin 2009; 5(4): 200-5.
59. Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008; 3(6): e2547.
60. Laniado-Laborín R. Smoking cessation intervention: an evidencebased approach. Postgrad Med 2010; 122(2): 74-82.
61. Bader P, McDonald P, Selby P. An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts. Tob Control 2009; 18(1): 34-42
62. Nides M. Update on pharmacologic options for smoking cessation treatment. Am J Med. 2008; 121(4 Suppl 1): S20-31.
63. Frishman WH. Smoking cessation pharmacotherapy. Ther Adv Cardiovasc Dis 2009; 3(4): 287-308.
64. Crain D, Bhat A. Current treatment options in smoking cessation. Hosp Pract (Minneap). 2010; 38(1): 53-61.
65. Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tob Control 2006; 15(4): 280-5.
66. Uhl GR, Liu QR, Drgon T, et al. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 2008; 65(6): 683-93.
67. Uhl GR, Drgon T, Johnson C, et al. Genome-wide association for smoking cessation success in a trial of precessation nicotine replacement. Mol Med 2010; 16(11-12): 513-26.
68. Rose JE, Behm FM, Dragon T, et al. Personalized smoking cessation: interactions between nicotine dose, dependence and quitsuccess genotype score. Mol Med 2010; 16(7-8): 247-53.
69. Gourlay SG, Forbes A, Marriner T, et al. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. BMJ 1995; 311(7001): 363-6.
70. Gonzales DH, Nides MA, Ferry LH, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther 2001; 69(6): 438-44.
71. Han ES, Foulds J, Steinberg MB, et al. Characteristics and smoking cessation outcomes of patients returning for repeat tobacco dependence treatment. Int J Clin Pract 2006; 60(9): 1068-74.
72. Rehm J, Mathers C, Popova S, et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcoholuse disorders. Lancet 2009; 373(9682): 2223-33.
73. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA. 1986; 256(11): 1449-55.
74. Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 281(14): 1318-25.
75. Chick J, Gough K, Falkowski W, et al. Disulfiram treatment of alcoholism. Br J Psychiatry 1992; 161: 84-9.
76. de Sousa A, De Sousa A. A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence. Alcohol Alcohol 2004; 39(6): 528-31.
77. de Sousa A, de Sousa A. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 2005; 40(6): 545-8.
78. de Sousa AA, De Sousa J, Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat 2008; 34(4): 460-3.
79. Laaksonen E, Koski-Jännes A, Salaspuro M, et al. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 2008; 43(1): 53-61.
80. Diehl A, Ulmer L, Mutschler J, et al. Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective longterm study in 353 alcohol-dependent patients. Alcohol Alcohol 2010; 45(3): 271-7.
81. Jørgensen CH, Pedersen B, Tønnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res 2011; 35(10): 1749-58.
82. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010a; 12: CD001867.
83. Roozen HG, de Waart R, van den Brink W. Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery. Eur Addict Res 2007; 13(4): 201-6.
84. Rubio G, Jiménez-Arriero MA, Ponce G, et al. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol 2001; 36(5): 419-25.
85. Martinotti G, Di Nicola M, Romanelli R, et al. High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients. Hum Psychopharmacol 2007; 22(3): 149-56.
86. Baltieri DA, Daró FR, Ribeiro PL, et al. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008; 103(12): 2035-44.
87. Martinotti G, Di Nicola M, Di Giannantonio M, et al. Aripiprazole in the treatment of patients with alcohol dependence: a doubleblind, comparison trial vs naltrexone. J Psychopharmacol 2009; 23(2): 123-9.
88. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs nefazodone for treatment of alcohol dependence. A placebocontrolled trial. Neuropsychopharmacology 2000; 22(5): 493-503.
89. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60(1): 92-9.
90. Anton RF, O'Malley SS, Ciraulo DA, et al. COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295(17): 2003-17.
91. Feeney GF, Connor JP, Young RM, et al. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol Alcohol 2006; 41(3): 321-7.
92. Heinälä P, Alho H, Kiianmaa K, et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 2001; 21(3): 287-92.
93. Karhuvaara S, Simojoki K, Virta A, et al. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res 2007; 31(7): 1179-87.
94. Kranzler HR, Tennen H, Armeli S, et al. Targeted naltrexone for problem drinkers. J Clin Psychopharmacol 2009; 29(4): 350-7.
95. Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 1998; 22(3): 573-9.
96. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361(9370): 1677-85.
97. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298(14): 1641-51.
98. Baltieri DA, Daró FR, Ribeiro PL, et al. Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients. Drug Alcohol Depend 2009; 105(1-2): 33-41.
99. Flórez G, García-Portilla P, Alvarez S, et al. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin Exp Res 2008; 32(7): 1251-9.
100. Arbaizar B, Diersen-Sotos T, Gómez-Acebo I, et al. Topiramate in the treatment of alcohol dependence: a meta-analysis. Actas Esp Psiquiatr 2010; 38(1): 8-12.
101. Khazaal Y, Zullino DF. Rebound of weight gain following topiramate cessation. Pharmacopsychiatry 2007; 40(2): 85-6.
102. Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des 2010; 16(19): 2103-12.
103. Cryan JF, Kaupmann K. Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci 2005; 26(1): 36-43.
104. Jacobson LH, Bettler B, Kaupmann K, et al. Behavioral evaluation of mice deficient in GABA(B(1)) receptor isoforms in tests of unconditioned anxiety. Psychopharmacology (Berl) 2007; 190(4): 541-53.
105. Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37(5): 504-8.
106. Garbutt JC, Kampov-Polevoy AB, Gallop R, et al. Efficacy and safety of baclofen for alcohol dependence: a randomized, doubleblind, placebo-controlled trial. Alcohol Clin Exp Res 2010; 34(11): 1849-57.
107. Tyacke RJ, Lingford-Hughes A, Reed LJ, et al. GABAB receptors in addiction and its treatment. Adv Pharmacol 2011; 58: 373-96.
108. Leone MA, Vigna-Taglianti F, Avanzi G, et al. Gammahydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev 2010; 2: CD006266.
109. Caputo F, Francini S, Stoppo M, et al. Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: an open comparative study. J Psychopharmacol 2009; 23(8): 883-90.
110. Nava F, Premi S, Manzato E, et al. Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumption. J Psychoactive Drugs 2006; 38(3): 211-7.
111. Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebocontrolled trial. J Clin Psychiatry 2007; 68(11): 1691-700.
112. Brower KJ, Myra Kim H, Strobbe S, et al. A randomized doubleblind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res 2008; 32(8): 1429-38.
113. Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 2008; 75(1): 34-56.
114. Kenna GA. Medications acting on the serotonergic system for the treatment of alcohol dependent patients. Curr Pharm Des 2010; 16(19): 2126-35
115. Pettinati HM, Volpicelli JR, Kranzler HR, et al. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000; 24(7): 1041-9.
116. Dundon W, Lynch KG, Pettinati HM, et al. Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. Alcohol Clin Exp Res 2004; 28(7): 1065-73.
117. Chick J, Aschauer H, Hornik K, et al. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend 2004; 74(1): 61-70.
118. Sellers EM, Toneatto T, Romach MK, et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994; 18(4): 879-85
119. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA 2000; 284(8): 963-71.
120. Kranzler HR, Pierucci-Lagha A, Feinn R, et al. Effects of ondansetron in early-versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res 2003; 27(7): 1150-5.
121. Mann K, Ackermann K, Diehl A, et al. Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebocontrolled trial. Psychopharmacology (Berl) 2006; 184(1): 115-21.
122. Kiefer F, Helwig H, Tarnaske T, et al. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res 2005; 11(2): 83-91.
123. Rohsenow DJ, Miranda R Jr, McGeary JE, et al. Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics. Exp Clin Psychopharmacol 2007; 15(3): 272-81.
124. Krishnan-Sarin S, Krystal JH, Shi J, et al. Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol Psychiatry 2007; 62(6): 694-7.
125. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28(8): 1546-52.
126. Tidey JW, Monti PM, Rohsenow DJ, et al. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in nontreatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 2008; 32(1): 58-66.
127. Verheul R, Lehert P, Geerlings PJ, et al. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl) 2005; 178(2-3): 167-73.
128. Ooteman W, Naassila M, Koeter MW, et al. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol 2009; 14(3): 328-37.
129. Kiefer F, Witt SH, Frank J, et al. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J 2011; 11(5): 368-74.
130. Brands B, Blake J, Sproule B, et al. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend 2004; 73(2): 199-207.
131. Sproule B, Brands B, Li S, et al. Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids. Can Fam Physician 2009; 55(1): 68-9, 69.e1-5.
132. Canfield MC, Keller CE, Frydrych LM, et al. prescription opioid use among patients seeking treatment for opioid dependence. J Addict Med 2010; 4(2): 108-113.
133. UNODC, World Drug Report 2010 (United Nations Publication, Sales No. E.10.XI.13).
134. Blanken P, van den Brink W, Hendriks VM, et al. Heroin-assisted treatment in the Netherlands: History, findings, and international context. Eur Neuropsychopharmacol 2010; 20 (Suppl 2): S105-58.
135. Amato L, Davoli M, Ferri M, et al. Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug Alcohol Depend. 2004; 73(3): 219-26.
136. Gowing L, Ali R, White JM. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev 2009a; 4: CD002021.
137. Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2009b; 3: CD002025.
138. Gowing L, Ali R, White JM. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database Syst Rev 2010; 1: CD002022.
139. Meader N. A comparison of methadone, buprenorphine and alpha(2) adrenergic agonists for opioid detoxification: a mixed treatment comparison meta-analysis. Drug Alcohol Depend 2010; 108(1-2): 110-4.
140. Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2006; 1: CD001333.
141. Naderi-Heiden A, Naderi A, Naderi MM, Rahmani-Didar F, Salimi AR, Gleiss A, Kasper S, Frey R. Ultra-rapid opiate detoxification followed by nine months of naltrexone maintenance therapy in Iran. Pharmacopsychiatry 2010; 43(4): 130-7.
142. Gibson AE, Degenhardt LJ. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug Alcohol Rev 2007; 26(4): 405-10.
143. Lobmaier P, Kornor H, Kunoe N, et al. Sustained-Release Naltrexone For Opioid Dependence. Cochrane Database Syst Rev 2008; 2: CD006140.
144. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63(2): 210-8.
145. Brooks AC, Comer SD, Sullivan MA, et al. Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment. J Clin Psychiatry 2010; 71(10): 1371-8.
146. Gastfriend et al. (2010) http://www.medscape.com/viewarticle/722907
147. Kampman (2008) http://www.medpagetoday.com/MeetingCoverage/APA/9373
148. Kunøe N, Lobmaier P, Vederhus JK, et al. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 2009; 194(6): 541-6.
149. Kunøe N, Lobmaier P, Vederhus JK, et al. Retention in naltrexone implant treatment for opioid dependence. Drug Alcohol Depend 2010; 111(1-2): 166-9.
150. Hulse GK, Morris N, Arnold-Reed D, et al. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry 2009; 66(10): 1108-15.
151. Lobmaier PP, Kunøe N, Gossop M, et al. Naltrexone implants compared to methadone: outcomes six months after prison release. Eur Addict Res 2010; 16(3): 139-45.
152. Hulse GK, Tait RJ, Comer SD, et al. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend 2005; 79(3): 351-7.
153. Reece AS. Favorable mortality profile of naltrexone implants for opiate addiction. J Addict Dis 2010; 29(1): 30-50
154. Tait RJ, Ngo HT, Hulse GK. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment. J Subst Abuse Treat 2008; 35(2): 116-24.
155. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; 3: CD002209.
156. Lind B, Chen S, Weatherburn D, et al. The effectiveness of methadone maintenance treatment in controlling crime. An Australian aggregate-level analysis. Journal of Criminology 2005; 45: 201-11.
157. Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend 2008; 94(1-3): 151-7.
158. Gowing L, Farrell M, Bornemann R, Sullivan LE, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2008; 2: CD004145.
159. Faggiano F, Vigna-Taglianti F, Versino E et al. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; 3: CD002208.
160. Buster MC, van Brussel GH, van den Brink W. An increase in overdose mortality during the first 2 weeks after entering or reentering methadone treatment in Amsterdam. Addiction 2002; 97(8): 993-1001
161. Davoli M, Bargagli AM, Perucci CA, et al. VEdeTTE Study Group. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007; 102(12): 1954-9.
162. Degenhardt L, Randall D, Hall W, et al. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009a; 105(1-2): 9-15.
163. Cornish R, Macleod J, Strang J, et al. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010; 341: c5475.
164. Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167(22): 2469-75.
165. Martell BA, Arnsten JH, Krantz MJ, et al. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005; 95(7): 915-8.
166. Ehret GB, Voide C, Gex-Fabry M, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006; 166(12): 1280-7.
167. Anchersen K, Clausen T, Gossop M, et al. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 2009; 104(6): 993-9.
168. Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150(6): 387-95
169. Byrne A, Hallinan R, Newman RG. Does electrocardiography improve methadone safety? Am J Health Syst Pharm 2010; 67(12): 968-9.
170. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; 2: CD002207.
171. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007; 11(9): 1-171, iii-iv.
172. Bell J, Trinh L, Butler B, et al. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009a; 104(7): 1193-200.
173. Bell JR, Butler B, Lawrance A, et al. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009b; 104(1-2): 73-7.
174. Degenhardt L, Randall D, Hall W, et al. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009b; 105(1-2): 9-15.
175. Fudala PJ, Bridge TP, Herbert S, et al. Buprenorphine/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349(10): 949-58.
176. Kamien JB, Branstetter SA, Amass LA. Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid dependent patients. Heroin Addict Relat Clin Probl 2008; 10 (4): 5-18.
177. Kakko J, Grönbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007; 164(5): 797-803.
178. Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs 2009; 69(5): 577-607.
179. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007; 88(1): 75-8.
180. Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, et al. Lack of reduction in buprenorphine injection after introduction of coformulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse 2009; 35(2): 68-72.
181. Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA 2010; 304(14): 1576-83.
182. Kastelic A, Dubajic G, Strbad E. Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction. 2008; 103(11): 1837-46
183. Mitchell TB, White JM, Somogyi AA, et al. Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction 2004; 99(8): 940-5
184. Kraigher D, Jagsch R, Gombas W, et al. Use of slow-release oral morphine for the treatment of opioid dependence. Eur Addict Res 2005; 11(3): 145-51.
185. Vasilev GN, Alexieva DZ, Pavlova RZ. Safety and efficacy of oral slow release morphine for maintenance treatment in heroin addicts: a 6-month open noncomparative study. Eur Addict Res 2006; 12(2): 53-60.
186. Frick U, Rehm J, Kovacic S, et al. A prospective cohort study on orally administered heroin substitution for severely addicted opioid users. Addiction 2006; 101(11): 1631-9.
187. WHO. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva, 2009.
188. Minozzi S, Amato L, Davoli M, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev 2008; (2): CD006754.
189. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004; 75(3): 233-40.
190. Winhusen T, Somoza E, Ciraulo DA, et al. A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence. Drug Alcohol Depend 2007; 91(2-3): 141-8.
191. Brodie JD, Case BG, Figueroa E, et al. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. Am J Psychiatry 2009; 166(11): 1269-77.
192. Alvarez Y, Farré M, Fonseca F, et al. Anticonvulsant drugs in cocaine dependence: a systematic review and meta-analysis. J Subst Abuse Treat 2010; 38(1): 66-73.
193. Silva de Lima M, Farrell M, Lima Reisser AARL et al. Antidepressants for cocaine dependence. Cochrane Database Syst Rev 2003; 2: CD002950
194. Winhusen TM, Somoza EC, Harrer JM, et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 2005; 100(Suppl 1): 68-77.
195. Ciraulo DA, Sarid-Segal O, Knapp CM, et al. Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence. Addiction 2005; 100 Suppl 1: 12-22.
196. Passos SR, Camacho LA, Lopes CS, et al. Nefazodone in outpatient treatment of inhaled cocaine dependence: a randomized double-blind placebo-controlled trial. Addiction 2005; 100(4): 489-94.
197. Johnson BA, Roache JD, Ait-Daoud N, et al. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend 2006; 84(3): 256-63.
198. Moeller FG, Schmitz JM, Steinberg JL, et al. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am J Drug Alcohol Abuse 2007; 33(3): 367-78.
199. Amato L, Minozzi S, Pani PP, et al. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev 2007; 3: CD006306.
200. Hamilton JD, Nguyen QX, Gerber RM, et al. Olanzapine in cocaine dependence: a double-blind, placebo-controlled trial. Am J Addict 2009; 18(1): 48-52.
201. Loebl T, Angarita GA, Pachas GN, et al. A randomized, doubleblind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. J Clin Psychiatry 2008; 69(3): 480-6.
202. Kennedy A, Wood AE, Saxon AJ, et al. Quetiapine for the treatment of cocaine dependence: an open-label trial. J Clin Psychopharmacol 2008; 28(2): 221-4.
203. Vorspan F, Bellais L, Keijzer L, et al. An open-label study of aripiprazole in nonschizophrenic crack-dependent patients. J Clin Psychopharmacol 2008; 28(5): 570-2
204. Soares B, Lima Reisser AARL, Farrell M, et al. Dopamine agonists for cocaine dependence. Cochrane Database Syst Rev 2003; 2: CD003352.
205. Focchi GR, Leite MC, Andrade AG, et al. Use of dopamine agonist pergolide in outpatient treatment of cocaine dependence. Subst Use Misuse 2005; 40(8): 1169-77.
206. Kampman KM, Dackis C, Lynch KG, et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend 2006; 85(2): 129-37.
207. Shoptaw S, Watson DW, Reiber C, et al. Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction 2005; 100 Suppl 1: 78-90
208. Mooney ME, Schmitz JM, Moeller FG, et al. tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend 2007; 88(2-3): 214-23.
209. Castells X, Casas M, Pérez-Mañá C, et al. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev 2010; 2: CD007380.
210. Mooney ME, Herin DV, Schmitz JM, et al. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2009; 101(1-2): 34-41.
211. Anderson AL, Reid MS, Li SH, Holmes T, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009; 104(1-2): 133-9.
212. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev 2010; 8: CD003410.
213. Herin DV, Rush CR, Grabowski J. Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Ann N Y Acad Sci 2010; 1187: 76-100.
214. Martínez-Raga J, Knecht C, Cepeda S. Modafinil: a useful medication for cocaine addiction? Review of the evidence from neuropharmacological, experimental and clinical studies. Curr Drug Abuse Rev 2008; 1(2): 213-21.
215. Blick SK, Keating GM. Lisdexamfetamine. Paediatr Drugs 2007; 9(2): 129-35; discussion 136-8.
216. Pani PP, Trogu E, Vacca R, et al. Disulfiram for the treatment of cocaine dependence. Cochrane Database Syst Rev 2010; 1: CD007024.
217. Pettinati HM, Kampman KM, Lynch KG, et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav 2008; 33(5): 651-67.
218. Oliveto A, Poling J, Mancino MJ, et al. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend 2011; 113(2-3): 184-91.
219. Peles E, Kreek MJ, Kellogg S, et al. High methadone dose significantly reduces cocaine use in methadone maintenance treatment (MMT) patients. J Addict Dis 2006; 25(1): 43-50.
220. Epstein DH, Schmittner J, Umbricht A, et al. Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug Alcohol Depend 2009; 101(1-2): 92-100.
221. Montoya ID, Gorelick DA, Preston KL, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 2004; 75(1): 34-48.
222. Schottenfeld RS, Pakes JR, Oliveto A, et al. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54(8): 713-20.
223. Strain EC, Stitzer ML, Liebson IA, et al. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl) 1994; 116(4): 401-6.
224. Schottenfeld RS, Chawarski MC, Pakes JR, et al. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry 2005; 162(2): 340-9.
225. Castells X, Kosten TR, Capellà D, et al. Efficacy of opiate maintenance therapy and adjunctive interventions for opioid dependence with comorbid cocaine use disorders: A systematic review and meta-analysis of controlled clinical trials. Am J Drug Alcohol Abuse 2009; 35(5): 339-49.
226. Schmitz JM, Stotts AL, Rhoades HM, et al. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav 2001; 26(2): 167-80.
227. Schmitz JM, Stotts AL, Sayre SL, DeLaune KA, Grabowski J. Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. Am J Addict 2004; 13(4): 333-41.
228. Schmitz JM, Lindsay JA, Green CE, et al. High-dose naltrexone therapy for cocaine-alcohol dependence. Am J Addict 2009; 18(5): 356-62.
229. Martell BA, Orson FM, Poling J, et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 2009; 66(10): 1116-23.
230. Kampman KM, Dackis C, Pettinati HM et al. A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence. Addict Behav 2011; 36(3): 217-21.
231. Bisaga A, Aharonovich E, Cheng WY, et al. A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. Drug Alcohol Depend 2010; 111(1-2): 97-104.
232. Reid MS, Angrist B, Baker S, et al. A placebo-controlled screening trial of celecoxib for the treatment of cocaine dependence. Addiction 2005; 100 (Suppl 1): 32-42.
233. Malcolm R, LaRowe S, Cochran K, et al. A controlled trial of amlodipine for cocaine dependence: a negative report. J Subst Abuse Treat 2005; 28(2): 197-204.
234. Kosten TR, Oliveto A, Sevarino KA, et al. Ketoconazole increases cocaine and opioid use in methadone maintained patients. Drug Alcohol Depend 2002; 66(2): 173-80.
235. Kampman K, Majewska MD, Tourian K, et al. A pilot trial of piracetam and ginkgo biloba for the treatment of cocaine dependence. Addict Behav 2003; 28(3): 437-48.
236. Huestis MA, Gorelick DA, Heishman SJ, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001; 58(4): 322-8.
237. Gorelick DA, Heishman SJ, Preston KL, et al. The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J 2006; 151(3): 754.e1-754.e5
238. Greenwald MK, Stitzer ML. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 2000; 59(3): 261-75.
239. Wachtel SR, de Wit H. Naltrexone does not block the subjective effects of oral Delta(9)-tetra-hydrocannabinol in humans. Drug Alcohol Depend 2000; 59(3): 251-60.
240. Haney M, Bisaga A, Foltin RW. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology (Berl) 2003; 166(1): 77-85
241. Haney M. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology 2007; 32(6): 1391-403.
242. Hart CL, Haney M, Ward AS, et al. Effects of oral THC maintenance on smoked marijuana self-administration. Drug Alcohol Depend 2002; 67(3): 301-9.
243. Cone EJ, Welch P, Lange WR. Clonidine partially blocks the physiologic effects but not the subjective effects produced by smoking marijuana in male human subjects. Pharmacol Biochem Behav 1988; 29(3): 649-52.
244. Haney M, Ward AS, Comer SD, et al. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl) 2001; 155(2): 171-9.
245. Haney M, Hart CL, Ward AS, et al. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl) 2003; 165(2): 157-65.
246. Haney M, Hart CL, Vosburg SK, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004; 29(1): 158-70.
247. Haney M, Hart CL, Vosburg SK, et al. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) 2008; 197(1): 157-68.
248. Tirado CF, Goldman M, Lynch K, et al. Atomoxetine for treatment of marijuana dependence: a report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study. Drug Alcohol Depend 2008; 94(1-3): 254-7.
249. McRae AL, Brady KT, Carter RE. Buspirone for treatment of marijuana dependence: a pilot study. Am J Addict 2006; 15(5): 404.
250. Winstock AR, Lea T, Copeland J. Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study. J Psychopharmacol 2009; 23(1): 84-93.
251. Nanjayya SB, Shivappa M, Chand PK, et al. Baclofen in cannabis dependence syndrome. Biol Psychiatry 2010; 68(3): e9-10
252. Levin FR, McDowell D, Evans SM, et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict 2004; 13(1): 21-32.
253. Carpenter KM, McDowell D, Brooks DJ, et al. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict 2009; 18(1): 53-64.
254. Vandrey R, Haney M. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs 2009; 23(7): 543-53.
255. Vann RE, Gamage TF, Warner JA, et al. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 2008; 94(1-3): 191-8.
256. Lorains FK, Cowlishaw S, Thomas SA. Prevalence of comorbid disorders in problem and pathological gambling: systematic review and meta-analysis of population surveys. Addiction 2011; [Epub ahead of print].
257. Grant JE, Kim SW. Quality of life in kleptomania and pathological gambling. Compr Psychiatry 2005; 46(1): 34-7.
258. Grant JE, Odlaug BL, Potenza MN, et al. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry 2010; 197(4): 330-1.
259. Dannon PN, Lowengrub K, Gonopolski Y, et al. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 2005; 28(1): 6-0.
260. Dannon PN, Lowengrub K, Musin E, et al. 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. J Clin Psychopharmacol 2007; 27(6): 620-4.
261. Kim SW, Grant JE, Adson DE, et al. A double-blind placebocontrolled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry 2002; 63(6): 501-7.
262. Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol 2003; 18(4): 243-9.
263. Pallanti S, Quercioli L, Sood E, et al. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 2002; 63(7): 559-64.
264. Fong T, Kalechstein A, Bernhard B, et al. A double-blind, placebocontrolled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav 2008; 89(3): 298-303.
265. McElroy SL, Nelson EB, Welge JA, et al. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry 2008; 69(3): 433-40.
266. Grant JE, Chamberlain SR, Odlaug BL, et al. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology (Berl) 2010; 212(4): 603-12.
267. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamatemodulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 2007; 62(6): 652-7.
268. Black DW, Shaw M, Forbush KT, et al. An open-label trial of escitalopram in the treatment of pathological gambling. Clin Neuropharmacol 2007; 30(4): 206-12.
269. Black DW, Arndt S, Coryell WH, et al. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebocontrolled, flexible-dose study. J Clin Psychopharmacol 2007; 27(2): 143-50.
270. Black DW, Shaw MC, Allen J. Extended release carbamazepine in the treatment of pathological gambling: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(5): 1191-4
271. Blanco C, Petkova E, Ibáñez A, et al. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry 2002; 14(1): 9-15.
272. Grant JE, Potenza MN, Hollander E, et al. A. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006; 163(2): 303-12.
273. Grant JE, Kim SW, Hartman BK. A double-blind, placebocontrolled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry 2008; 69(5): 783-9.
274. Hollander E, DeCaria CM, Mari E, et al. Short-term single-blind fluvoxamine treatment of pathological gambling. Am J Psychiatry 1998; 155(12): 1781-3.
275. Hollander E, DeCaria CM, Finkell JN, et al. A randomized doubleblind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 2000; 47(9): 813-7.
276. Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol 2001; 16(5): 285-9.
277. Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001; 49(11): 914-21.
278. Pallanti S, Baldini Rossi N, Sood E, et al. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. J Clin Psychiatry 2002; 63(11): 1034-9.
279. Saiz-Ruiz J, Blanco C, Ibáñez A, et al. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry 2005; 66(1): 28-33.
280. Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry 2002; 63(1): 44-8.
281. Berlin HA, Braun A, Simeon D, et al. A double-blind, placebocontrolled trial of topiramate for pathological gambling. World J Biol Psychiatry 2011; 12. [Epub ahead of print]
282. Lahti T, Halme JT, Pankakoski M, et al. Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study. Psychopharmacol Bull 2010; 43(3): 35-44.
283. Achab S, Khazaal Y. Psychopharmacological treatment in pathological gambling: a critical review. Curr Pharm Des 2011; 17(14): 1389-95.
284. Leshner AI. Addiction is a brain disease, and it matters. Science 1997; 278(5335): 45-7.
285. Kampman KM. What's new in the treatment of cocaine addiction? Curr Psychiatry Rep 2010; 12(5): 441-7.
286. Ooteman W, Verheul R, Naassila M, et al. Patient-treatment matching with anti-craving medications in alcohol dependent patients: a review on phenotypic, endophenotypic and genetic indicators. J Subst Use 2005; 10: 75-96.
287. Grant JE, Kim SW, Hollander E, et al. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology (Berl) 2008b; 200(4): 521-7.
288. Kenna GA, Nielsen DM, Mello P, et al. Pharmacotherapy of dual substance abuse and dependence. CNS Drugs 2007; 21(3): 213-37.
289. Simkin DR, Grenoble S. Pharmacotherapies for adolescent substance use disorders. Child Adolesc Psychiatr Clin N Am 2010; 19(3): 591-608.
290. Coleman T, Chamberlain C, Cooper S, et al. Efficacy and safety of nicotine replacement therapy for smoking cessation in pregnancy: systematic review and meta-analysis. Addiction 2011; 106(1): 52-61.
291. Cleary BJ, Donnelly J, Strawbridge J, et al. Methadone dose and neonatal abstinence syndrome-systematic review and metaanalysis. Addiction 2010; 105(12): 2071-84.
292. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363(24): 2320-31.
293. Unger A, Jung E, Winklbaur B, et al. Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine. J Addict Dis 2010; 29(2): 217-30.
294. De Wildt WA, Schippers GM, Van Den Brink W, et al. Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems? Alcohol Alcohol 2002; 37(4): 375-82.
295. Huestis MA, Boyd SJ, Heishman SJ, et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology Berl 2007; 194(4): 505-15.
296. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010; 9: CD004332.
297. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcoholdependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370(9603): 1915-22.
298. Anton RF, Oroszi G, O'Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008; 65(2): 135-44.